What is the Medicare GLP-1 Bridge program?

The Medicare GLP-1 Bridge is a temporary program running from July 2026 through 2027 that allows eligible Medicare beneficiaries to access GLP-1 weight loss medications (Wegovy and Zepbound) at a flat $50 per month copay. It is designed to bridge the gap until broader Medicare coverage of weight loss drugs potentially becomes available.

Does the Medicare GLP-1 Bridge cover Ozempic?

No. The Bridge program covers Wegovy and Zepbound for weight management only. Ozempic is indicated for Type 2 diabetes and is already covered under regular Medicare Part D for that use. If you take Ozempic for diabetes, your coverage continues through standard Part D benefits.

What BMI do I need to qualify for the Medicare GLP-1 Bridge?

You need a BMI of 35 or higher. Your doctor must submit a prior authorization to a central processor to verify you meet the BMI and health requirements. You are ineligible if you have already filled a GLP-1 prescription under Part D in 2026 or have a diagnosis like Type 2 diabetes that qualifies you for standard Part D GLP-1 coverage.

Does the $50 copay count toward my Medicare deductible?

No. The $50 monthly copay is a flat fee outside of your regular Part D benefits. It does not count toward your Part D deductible or your annual out-of-pocket spending cap. This is an important distinction because it means this spending does not bring you closer to catastrophic coverage.

Trending

Medicare GLP-1 Bridge Program 2026: $50/Month Weight Loss Drugs Explained

Updated September 2026 · 8 min read

For millions of Medicare beneficiaries who have wanted access to weight loss medications like Wegovy and Zepbound but could not afford the $800-$1,350 monthly retail price, the new Medicare GLP-1 Bridge program offers a significant breakthrough: a flat $50 per month copay. Here is everything you need to know about eligibility, covered drugs, limitations, and how it affects your Medicare costs.

Do You Qualify? Check Your BMI First

The GLP-1 Bridge requires BMI of 35 or higher.

Check Your BMI →Compare Drug Costs

What the Program Covers

Covered drugs: Wegovy (semaglutide) and Zepbound (tirzepatide) — for weight management only
NOT covered: Ozempic (already covered under Part D for diabetes), Mounjaro (diabetes indication)
Cost: flat $50 per month copay regardless of your usual Medicare coverage phases
Duration: July 2026 through 2027 (temporary demonstration program)

Eligibility Requirements

Enrolled in a Medicare Part D plan or Medicare Advantage plan with drug coverage
BMI of 35 or higher — check your BMI here
Taking the GLP-1 medication specifically for weight management
Have NOT filled a GLP-1 prescription under Part D earlier in 2026
Do NOT have a diagnosis (Type 2 diabetes, obstructive sleep apnea, etc.) that already qualifies you for GLP-1 coverage under standard Part D
Doctor must submit prior authorization to a central CMS processor

Important Limitations

The $50 copay does NOT count toward your deductible or out-of-pocket cap. This is a critical detail many people miss. Under normal Part D benefits, your spending counts toward your annual deductible and the $2,100 out-of-pocket cap (for 2026). The Bridge program copay sits outside your regular benefits — it does not bring you closer to catastrophic coverage.

This means if you are also taking expensive medications under Part D, your Bridge spending is completely separate from your progress toward the out-of-pocket cap.

Cost Comparison: Bridge vs Other Options

Medicare GLP-1 Bridge: $50/month (if eligible)
Standard Part D (for diabetes): varies by plan, but $2,100 annual OOP cap applies
Retail without insurance: $800-$1,350/month
Manufacturer self-pay (NovoCare): $349/month for Wegovy
GoodRx coupons: starting around $199/month
Manufacturer patient assistance: potentially $0-$25/month if income under 400% FPL

Compare all your options: Prescription Cost Comparison tool →

Looking Ahead: 2027 Negotiated Prices

CMS selected Ozempic, Rybelsus, and Wegovy for the second round of Medicare drug price negotiations. The negotiated price of $274 for a 30-day supply takes effect in 2027. This will significantly reduce costs for Medicare beneficiaries using these drugs under standard Part D, potentially making the Bridge program less necessary for some enrollees.

What to Do Now

Check your BMI with our free BMI Calculator — you need 35+ to qualify
Talk to your doctor about whether a GLP-1 medication is right for you
Contact your Part D plan to confirm they participate in the Bridge program
Compare costs using our Prescription Cost Comparison — the Bridge at $50/month may or may not be your cheapest option depending on other programs available to you
Understand your overall Medicare costs with our Out-of-Pocket Calculator

Sources: CMS, AARP, U.S. News, GoodRx, Medical News Today. Program details may change — verify current eligibility and coverage with Medicare.gov or your Part D plan. This article is for educational purposes only and is not medical or financial advice.